Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Medical - Diagnostics & Research

Healthcare
$1.59 +2.44%

+$0.13 today

Market cap
$52.08M
Beta
1.79
P/E (TTM)
-3.9
EPS (TTM)
-$1.39
52W Low $2.33High $8.51

Volume 0.64M

Average 0.38M

IMDX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Insight Molecular Diagnostics Inc.NASDAQ: IMDX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$605.5K, compared with $1.33M a year earlier. Trailing-twelve-month gross profit was $379.5K.

Context

  • Gross profit amounted to 4.7% of revenue in FY2025, down 34.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$605.5K or moves back toward the trailing-twelve-month quarterly average of $94.88K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$605.5K-222.1% QoQ
Last fiscal yearDec 2025
$190K-74.3% YoY
LTMMar 2026
$379.5K-81.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-145.7%——
1 year-74.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
190K USD
Year-over-year change
-74.3%
4-year CAGR
-39.5%

Gross Profit vs competitors

How IMDX compares with its peers on the latest reported figures

  • IMDX's LTM Mar 2026 gross profit of $379.5K is the 9th highest of the 10 companies compared; the peer median is $16.33M.
  • Its year-over-year change of -81.2% is the 8th highest of 9, against a peer median of -19.1%.
  • Gross profit amounts to 19.5% of revenue for IMDX, versus a peer median of 93.3%.
IMDX Competitors Peer median
Gross Profit for IMDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026$65.55M +83.9%-15.3%83.9%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M +50.2%—92.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M -45.8%-31.5%100.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M -2.5%-3.5%94.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M +133.3%—97.7%
OABIOmniAb, Inc.LTM Mar 2026$10.25M -61.7%—35.5%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.14M -35.6%—72.2%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$1.69M —-34.1%94.7%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$379.5K -81.2%—19.5%
PEPGPepGen Inc.LTM Mar 2026-$1.72M -351.6%——
Peer median (excluding IMDX) $16.33M-19.1%-23.4%93.3%

Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.2M958K1.5M1.88M4.06M
Cost of Revenue778K976K1.09M1.14M3.87M
Gross Profit1.42M(18K)413K740K190K
Gross Margin64.6%-1.9%27.5%39.3%4.7%
Research & Development5.04M7.3M9.29M9.84M15.9M
Selling, General & Admin20.39M21.53M13.29M13.79M16.98M
Operating Expenses55.15M17.98M25.55M61.78M30.77M
Depreciation & Amortization4.21M5.22M1.68M1.56M2.2M
EBITDA(48.46M)(13.31M)(23.12M)(59.02M)(47.92M)
EBITDA Margin-2204.6%-1389.2%-1538.5%-3137.4%-1181.7%
Operating Income(53.73M)(18M)(25.14M)(61.04M)(30.58M)
Operating Margin-2444.3%-1878.6%-1672.4%-3245.1%-754.1%
Interest Income00000
Interest Expense209K83K52K84K109K
Other Income / Expenses854K(615K)281K378K(19.64M)
Income Before Tax(52.87M)(18.61M)(24.86M)(60.66M)(50.22M)
Pre-Tax Margin-2405.4%-1942.8%-1653.7%-3225.0%-1238.5%
Income Tax Expense(9.26M)0000
Net Income(64.1M)(72.9M)(27.78M)(60.66M)(50.22M)
Net Margin-2916.2%-7609.8%-1848.4%-3225.0%-1238.5%
EPS (Basic)(14.40)(20.00)(3.75)(4.66)(1.65)
EPS (Diluted)(14.40)(20.00)(3.75)(4.66)(1.65)
Weighted Avg Shares4.45M5.54M7.65M13.07M30.48M
Weighted Avg Shares (Diluted)4.45M5.54M7.65M13.07M30.48M

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

Intrinsic Alpha fair value

Locked

Current Price

$1.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.